Research Scientists

Minhee Kang

Senior Research Scientist

Biostatistics

mkang@hsph.harvard.edu

Links

Catalyst Profile

Overview

Education and Training
Awards and Honors

Ph.D., Biostatistics
Harvard University, Cambridge, MA

Sc.B., Applied Mathematics
Brown University, Providence, RI

M.S., Operations Research
Cornell University, Ithaca, NY

Howard Hughes Medical Institute Predoctoral Fellowship in Biological Sciences1998-2003

Bibliography

Immunogenicity and Safety of Hepatitis B vaccine with a Toll-like Receptor 9 Agonist Adjuvant (HEPLISAV-B) in HBV Vaccine-naive People with HIV.

Marks KM, Kang M, Umbleja T, Avihingsanon A, Sugandhavesa P, Cox AL, Vigil K, Perazzo H, Price JC, Katsidzira L, Vernon C, Alston-Smith B, Sherman KE.

Clin Infect Dis. 2023 Apr 05. PMID: 37017075

Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS).

Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG.

Open Forum Infect Dis. 2023 Mar. 10(3):ofad115. PMID: 37008564

Effects of Sex, Existing Antibodies, and HIV-1-Related and Other Baseline Factors on Antibody Responses to Quadrivalent HPV Vaccine in Persons With HIV.

Kang M, Umbleja T, Ellsworth G, Aberg J, Wilkin T.

J Acquir Immune Defic Syndr. 2022 04 01. 89(4):414-422. PMID: 34907980

Incorporating estimands into clinical trial statistical analysis plans.

Kang M, Kendall MA, Ribaudo H, Tierney C, Zheng L, Smeaton L, Lindsey JC.

Clin Trials. 2022 06. 19(3):285-291. PMID: 35257600

Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.

Hawkins C, Kang M, Bhattacharya D, Cloherty G, Kuhns M, Matining R, Thio C, Samaneka W, Chinula L, Mulinda N, Badal-Faesen S, Sugandhavesa P, Lama J, Gaseitsiwe S, Holzmayer V, Anderson M, Murphy R, Peters M.

AIDS. 2022 06 01. 36(7):975-984. PMID: 35165216

Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).

Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG.

Open Forum Infect Dis. 2021 Dec. 8(12):ofab511. PMID: 34926713

Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy.

Nyirenda M, Ngongondo M, Kang M, Umbleja T, Krown SE, Godfrey C, Samaneka W, Mngqibisa R, Hoagland B, Mwelase N, Caruso S, Martinez-Maza O, Dittmer DP, Borok M, Hosseinipour MC, Campbell TB.

J Acquir Immune Defic Syndr. 2020 08 01. 84(4):422-429. PMID: 32265361

Interim monitoring in a treatment strategy trial with a composite primary endpoint.

Kang M, Grund B, Hunsberger S, Glidden D, Volberding P.

Contemp Clin Trials. 2019 11. 86:105846. PMID: 31520741

PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals.

Sherman KE, Rouster SD, Kang M, Umbleja T, Sterling R, Butt AA.

Dig Dis Sci. 2018 11. 63(11):2969-2974. PMID: 30218427

Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1.

Cespedes MS, Kang M, Kojic EM, Umbleja T, Godfrey C, Webster-Cyriaque JY, Masih R, Firnhaber C, Grinsztejn B, Saah A, Cu-Uvin S, Aberg JA.

Papillomavirus Res. 2018 12. 6:15-21. PMID: 30118852

VIEW MORE PUBLICATIONS